$2,399.00 – $6,599.00
Talzenna is indicated as monotherapy for the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations who have previously received anthracyclines and/or taxanes in the neoadjuvant or adjuvant setting or for locally advanced or metastatic disease, unless patients are considered ineligible for such treatment. Patients with HR-positive breast cancer must have received prior endocrine therapy or be considered ineligible for endocrine therapy.
Active ingredient: talazoparib
Prescription medicine
| Дозировка | 0,25 Mg, 1.0Mg |
|---|
